Pfizer denies Ranbaxy buyout talk

Pfizer said it isn't buying a majority stake in Ranbaxy Laboratories, quashing rumors that it might counter Daiichi Sankyo's bid for the Indian drugmaker. "I can tell you that we have no intention of buying the company," a spokesman told Dow Jones. Report

Suggested Articles

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…